Eden Research (EDEN) AI Stock Analysis

• Market Cap: £19.20M
• Dividend Yield: N/A
• Average Volume (3M): 564.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: -8.14%
• EPS Growth: -51.72%
• Country: UK
• Employees: 23
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): >-0.01
• Shares Outstanding: 533,352,540
• 10 Day Avg. Volume: 506,108
• 30 Day Avg. Volume: 564,076
• PEG Ratio: 0.14
• Price to Book (P/B): 1.78
• Price to Sales (P/S): 4.90
• P/FCF Ratio: -5.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: 3.50p ▲(34.62% Upside)

The score is held back primarily by weak financial quality—ongoing losses and persistently negative cash flow—despite some revenue growth and a comparatively stable balance sheet. Technicals are currently strong with price above major moving averages, but overbought signals raise pullback risk. Valuation is constrained by loss-making status (negative P/E) and the absence of a dividend yield.

Positive Factors

Sustainable product focus

Eden's focus on plant-based biopesticides targets the durable structural shift toward sustainable agriculture. Differentiated, eco-friendly formulations can drive long-term adoption by growers and distributors, benefiting from regulatory tailwinds limiting synthetic chemical use.

Diverse revenue channels

Multiple monetization paths—direct sales, licensing of patented technologies, partnerships and R&D collaborations—reduce single-channel dependence. Licensing and partner commercialization can scale revenue with lower capital intensity and enable wider market access over time.

Relatively strong equity position

A high equity ratio provides financial resilience against cyclical shocks and supports continued R&D and product commercialization without immediate leverage. This capital buffer improves the company's ability to pursue long-term product development and sustain operations during growth phases.

Negative Factors

Negative cash flow

Persistent negative operating and free cash flow undermines the firm's ability to self-fund expansion and R&D. Ongoing cash burn increases reliance on external financing or equity raises, which can dilute shareholders and create execution risk for multi-year commercialization strategies.

Loss-making operations

Continued negative EBIT and net income indicate the company has not achieved sustainable profitability. Sustained losses limit reinvestment capacity, elevate financing needs, and require material margin improvement or scale to achieve break-even over the medium term.

Eroding shareholder equity

A trend of declining stockholders' equity erodes the capital cushion available to absorb losses and reduces borrowing capacity. If losses continue, the weakened equity base raises solvency and refinancing risk, constraining long-term growth and partnership opportunities.

Eden Research Business Overview & Revenue Model

Company Description

Eden Research plc is a UK-based company that operates in the agricultural sector, specializing in the development and commercialization of sustainable biopesticides and natural products. The company primarily focuses on providing eco-friendly solutions for crop protection and enhancing plant health, catering to the increasing demand for sustainable agricultural practices. Eden's core products include natural formulations derived from plant-based materials, aimed at reducing reliance on synthetic chemicals in farming.

How the Company Makes Money

Eden Research generates revenue primarily through the sale of its biopesticide products and licensing agreements for its patented technologies. The company earns income from direct sales to agricultural distributors and growers, as well as through partnerships with larger agricultural companies that utilize its formulations in their product lines. Additional revenue streams include research and development collaborations, where Eden partners with other firms or institutions to develop new products, and potentially royalty income from licensing its intellectual property. Key partnerships with industry players enhance its market reach and facilitate entry into new markets, contributing to its overall earnings.

Eden Research Financial Statement Overview

Summary

Eden Research shows revenue growth potential but struggles with profitability and cash flow issues. The balance sheet is stable, but financial constraints may limit future growth.

Income Statement

Eden Research shows a positive trend in revenue growth, with an increase from previous years, indicating potential market expansion. However, the company struggles with profitability, as evidenced by negative EBIT and net income figures. The gross profit margin is moderate, but net profit margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

The company maintains a solid equity position with a high equity ratio, indicating financial stability. However, the debt-to-equity ratio, while low, highlights limited leverage which could constrain growth. The declining stockholders' equity over the years suggests potential risk if losses persist.

Cash Flow

Eden Research faces significant cash flow challenges, with consistently negative free cash flow and operating cash flow figures. The company has not demonstrated consistent improvement in cash flow ratios, which could impact its ability to fund operations without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.62M	4.30M	3.19M	1.83M	1.23M	1.37M
Gross Profit	1.39M	1.87M	1.77M	207.14K	28.32K	9.63K
EBITDA	-1.93M	-1.59M	-6.24M	-1.83M	-2.72M	-1.87M
Net Income	-2.35M	-1.91M	-6.49M	-2.24M	-2.79M	-2.27M
Balance Sheet
Total Assets	13.46M	15.41M	16.59M	12.91M	15.03M	16.92M
Cash, Cash Equivalents and Short-Term Investments	1.85M	3.67M	7.41M	1.99M	3.83M	7.29M
Total Debt	571.86K	168.73K	229.77K	355.32K	398.35K	415.25K
Total Liabilities	2.85M	3.57M	3.05M	2.17M	2.20M	2.00M
Stockholders Equity	10.58M	11.82M	13.52M	10.72M	12.80M	14.91M
Cash Flow
Free Cash Flow	-710.00K	-3.60M	-1.80M	-1.74M	-3.34M	-2.92M
Operating Cash Flow	-209.90K	-1.01M	-1.70M	-683.10K	-1.62M	-1.02M
Investing Cash Flow	-2.72M	-2.48M	-1.72M	-1.05M	-1.73M	-1.90M
Financing Cash Flow	-150.87K	-155.53K	8.90M	-150.35K	-90.39K	9.71M

Eden Research Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EDEN, the sentiment is Positive. The current price of 2.6 is below the 20-day moving average (MA) of 2.75, above the 50-day MA of 2.47, and below the 200-day MA of 2.99, indicating a bullish trend. The MACD of 0.24 indicates Negative momentum. The RSI at 88.56 is Negative, neither overbought nor oversold. The STOCH value of 84.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EDEN.

Eden Research Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TET	67 Neutral	£127.34M	11.65	8.02%	4.08%	1.12%	-0.70%
CRDA	65 Neutral	£3.80B	27.09	6.17%	3.45%	2.36%	-13.99%
ELM	64 Neutral	£969.41M	-16.97	3.37%	1.34%	-11.78%	-92.61%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ITX	54 Neutral	£14.50M	-16.78	-12.88%	―	25.56%	35.12%
SYNT	51 Neutral	£99.77M	-1.22	-7.26%	―	-4.41%	2.29%
EDEN	49 Neutral	£19.20M	-8.18	-20.21%	―	-8.14%	-51.72%

Eden Research Corporate Events

Eden Research Wins First South American Approval for Novellus+ in Chile

Eden Research has secured its first regulatory authorisation in South America with the approval of its fungicide Novellus+ in Chile for use on wine and table grapes to control grey mould and powdery mildew. The product, which offers residue-free protection and can be applied up to one day before harvest, will be exclusively distributed by Sipcam Chile SpA in a market that is both a global leader in wine and grape exports and a rapidly growing adopter of biological crop protection. This authorisation marks a strategic milestone for Eden, opening access to a sizable and expanding Chilean crop protection market and positioning the company to benefit from the country’s regulatory and industry push toward more sustainable agricultural practices, with plans to extend Novellus+ to additional high-value crops over time.

The most recent analyst rating on (GB:EDEN) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Eden Research stock, see the GB:EDEN Stock Forecast page.

Eden Research Wins French Approval for Mevalone Use on Grapes

Eden Research has secured regulatory approval in France for a label extension of its Mevalone biofungicide, allowing its use on grapes to control downy and powdery mildew, two of the country’s most damaging vineyard diseases. The move opens a meaningful growth avenue in one of the world’s largest and most mildew-affected grape markets, where climate change, tightening restrictions on copper and synthetic fungicides, and rapid expansion of organic viticulture are accelerating demand for biopesticides; Eden estimates the opportunity could generate up to €8 million in annual peak revenue under current label conditions, although it is maintaining its existing market guidance for now as the company and its partners integrate the product into the upcoming growing season.

The most recent analyst rating on (GB:EDEN) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Eden Research stock, see the GB:EDEN Stock Forecast page.

Eden Research Partners with Syngenta for Exclusive Distribution of Fungicide Evelta™

Eden Research plc has appointed Syngenta Crop Protection AG as its exclusive distribution partner for its novel fungicide product Evelta™, targeting the professional ornamental crop market in multiple EU countries and the UK. This collaboration marks Eden’s first commercial agreement with one of the world’s largest crop protection companies, aligning with its goal of expanding its market reach and reinforcing its commitment to delivering sustainable solutions to growers while enhancing operational execution and stakeholder value.

The most recent analyst rating on (GB:EDEN) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Eden Research stock, see the GB:EDEN Stock Forecast page.

Eden Research Expands 3LOGY Biofungicide Approval in Italy

Eden Research plc announced that its biofungicide 3LOGY has received approval in Italy for use on additional crops and diseases, expanding its application beyond grapes to include legumes, avocados, carrots, and more. This label extension significantly increases 3LOGY’s market reach in Italy by over twenty thousand hectares, enhancing its role in sustainable agriculture and strengthening Eden’s competitive position in the fungicide market.

The most recent analyst rating on (GB:EDEN) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Eden Research stock, see the GB:EDEN Stock Forecast page.

Eden Research’s Ecovelex 2025 Gains Temporary Approval in Italy

Eden Research has announced that its product, Ecovelex 2025, has received temporary authorization in Italy for use as a bird repellent seed treatment on maize for the 2026 growing season. This approval allows Eden to continue selling Ecovelex in Italy, providing a sustainable alternative to conventional chemicals no longer approved in the EU and UK. The product, which repels birds by emitting an unpleasant taste or odor, is part of Eden’s strategy to support sustainable agriculture and awaits full EU-wide authorization. This development is significant for local maize farmers and strengthens Eden’s market position in sustainable crop protection solutions.

The most recent analyst rating on (GB:EDEN) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Eden Research stock, see the GB:EDEN Stock Forecast page.